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Abstract: The advantages of blood pressure (BP) control on the risks of heart failure and 
stroke are well established. The renin-angiotensin system plays an important role in volume 
homeostasis and BP regulation and is a target for several groups of antihypertensive drugs. 
  Angiotensin II receptor blockers represent a major class of antihypertensive compounds. 
  Candesartan cilexetil is an angiotensin II type 1 (AT[1]) receptor antagonist (angiotensin receptor 
blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone 
system. Oral candesartan 8–32 mg once daily is recommended for the treatment of adult patients 
with hypertension. Clinical trials have demonstrated that candesartan cilexetil is an effective 
agent in reducing the risk of cardiovascular mortality, stroke, heart failure, arterial stiffness, renal 
failure, retinopathy, and migraine in different populations of adult patients including patients 
with coexisting type 2 diabetes, metabolic syndrome, or kidney impairment. Clinical evidence 
confirmed that candesartan cilexetil provides better antihypertensive efficacy than losartan and is 
at least as effective as telmisartan and valsartan. Candesartan cilexetil, one of the current market 
leaders in BP treatment, is a highly selective compound with high potency, a long duration of 
action, and a tolerability profile similar to placebo. The most important and recent data from 
clinical trials regarding candesartan cilexetil will be reviewed in this article.
Keywords: angiotensin receptor blockers, candesartan, candesartan cilexetil, clinical trials, 
efficacy studies, safety, blood pressure
Introduction to the development and use of sartans 
in the treatment of cardiovascular disease
Hypertension is a major risk factor for morbidity and mortality through its effects 
on target organs like heart, brain, and kidneys. More intensive treatment for the 
effective control of blood pressure (BP) significantly reduces morbidity and 
mortality.1,2 The renin angiotensin system (RAS) is a coordinated hormonal   cascade 
of major clinical   importance in the regulation of BP.2 The principal peptide of RAS is 
angiotensin II, which acts by binding to one of the two major angiotensin II receptors 
AT(1) and AT(2). Angiotensin II through AT(1) receptor mediates a vast majority of 
biologically detrimental actions. Candesartan cilexetil is one of a number of drugs of 
the angiotensin II receptor blocker (ARB) class. Candesartan cilexetil is converted 
to the angiotensin II receptor antagonist candesartan during absorption from the 
gastrointestinal tract. The selective and competitive binding of candesartan to the AT(1) 
receptor prevents binding of angiotensin II, a key mediator in the renin-angiotensin 
system.3,4 It was administrated for the first time in animal models in 1992 and in   clinical 
trials 2 years later.5,6 Its use has increased dramatically in the treatment of stroke, 
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heart failure, diabetic renal disease, and most recently in 
preventing the development of or delaying the progression 
of diabetic retinopathy.1–4
Overview of differential 
pharmacology of candesartan 
compared to other sartans
ARBs do not modulate the amount of circulating angio-
tensin II; rather, they inhibit the binding of angiotensin II to 
AT(1). AT(1) receptors are located primarily in the   vascular 
smooth muscle and adrenal glands. ARBs inhibit most 
of the biological effects of angiotensin II:   contraction 
of vascular smooth muscle, pressor responses, thirst, 
aldosterone secretion, vasopressin release, release of adrenal 
  catecholamines, augmentation of noradrenergic neurotrans-
mission, increase of sympathetic tone, change in renal 
  function, and cellular hypertrophy and hyperplasia. Because 
they do not have a direct effect on the angiotensin-converting 
enzyme (ACE), ARBs do not directly affect bradykinin; 
however, they may increase nitric oxide release and inhibit 
its degradation.7,8
ARBs differ in their AT(1) binding characteristics. 
Binding is classified as surmountable or insurmountable, 
according to the shifting of the angiotensin II concentration-
response curves to the right. Surmountable antagonism 
does not change the maximal angiotensin II response; 
insurmountable antagonism reduces the response. Therefore, 
insurmountable binding cannot be overcome by   increasing 
concentrations of angiotensin II.9 The insurmountable 
behavior of candesartan is linked to the presence of a carboxyl 
group at its imidazole-derived moiety. But telmisartan and 
valsartan show insurmountable behavior despite the absence 
of a carboxyl group.10
The AT(1) receptor can be activated by mechanical 
stress through an angiotensin II-independent mechanism. 
Without the involvement of angiotensin II, mechanical 
stress not only activates extracellular signal-regulated 
kinases and increases phosphoinositide production in vitro, 
but also induces cardiac hypertrophy in vivo. Mechanical 
stretch induces association of the AT(1) receptor with Janus 
kinase 2, and translocation of G proteins into the cytosol. All 
of these events are inhibited by the AT(1) receptor blocker 
candesartan cilexetil. Candesartan cilexetil, olmesartan, and 
valsartan can stabilize the AT(1) receptor in an inactive state, 
called “inverse agonism”, in the absence of angiotensin II, 
thereby attenuating cardiac hypertrophy, independent of BP 
reduction.10–13 There is also another mechanism that explains 
the link between cardiac stretching and the AT(1) receptor. 
Mechanical stress stimulates the secretion of angiotensin II 
from secretory granules through natural messengers inside 
cardiac myocites.10
There are some ARBs that can function as a partial 
  agonist of peroxisome proliferator activator receptor gamma 
and improve carbohydrate and lipid metabolism, such as 
candesartan cilexetil and telmisartan, but only telmisartan 
can achieve this effect with therapeutic doses.14
The AT(2) receptor remains mysterious, especially in 
AT(2)-coupled interference with proinflammatory pathways. 
It is thought that effects mediated by the AT(2) receptor 
include inhibition of cell growth, fetal tissue development, 
modulation of extracellular matrix, neuronal regeneration, 
apoptosis, cellular differentiation, and, possibly, vasodilation 
and left ventricular hypertrophy. ARBs in clinical use are 
more than 10,000-fold selective for the AT(1) receptor versus 
the AT(2) receptor, with one of the highest selective being 
candesartan cilexetil.10–13 The pharmacological properties 
of candesartan cilexetil and other ARBs are presented in 
Table 1.10–15
Clinical use and efficacy studies  
of candesartan cilexetil  
in comparison to other sartans
Several clinical trials have shown the efficacy of candesartan 
cilexetil in the treatment of patients with hypertension, left 
ventricular dysfunction, acute coronary syndrome, heart 
failure, arterial compliance, retinopathy, nephropathy, stroke, 
atrial fibrillation, and migraine, and also the cost effectiveness 
of candesartan cilexetil. Some of them are summarized in 
Table 2 and detailed after that.
Heart failure
CHARM-Added
The Candesartan in Heart failure: Assessment of Reduction 
in Mortality and morbidity (CHARM)-Added trial 
investigated the efficacy of 32 mg candesartan cilexetil 
versus placebo in 2548 patients already being treated with an 
ACE inhibitor for chronic heart failure and a left ventricular 
ejection fraction less than 40%.16 Patients were observed 
for a median of 41 months. The addition of candesartan 
cilexetil significantly reduced the primary outcome of 
cardiovascular death or hospitalization for chronic heart 
failure compared with placebo (38% vs 42%, HR: 0.85, 
P = 0.011). Candesartan cilexetil also reduced the need for 
multiple admissions for chronic heart failure, suggesting a 
sustained and durable benefit.
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CHARM–Alternative
This trial investigated whether 32 mg candesartan cilexetil 
would improve the clinical outcomes of 2028 patients 
with congestive heart failure and left ventricular systolic 
dysfunction (ejection fraction less than 40%) who were 
intolerant to ACE inhibitors.17 Candesartan cilexetil 
significantly reduced the relative risk of cardiovascular 
mortality or hospital admission for heart failure by 23% 
compared with placebo (HR: 0.77, 95% CI: 0.67–0.89, 
P = 0.0004). The clinical benefit was also observed in patients 
with nonfatal myocardial infarction, nonfatal stroke, and 
coronary revascularization. Importantly, hospitalization for 
worsening heart failure was reduced by 32% (P , 0.0001) 
with candesartan cilexetil.
CHARM-Preserved
This trial investigated whether 32 mg candesartan cilexetil 
could improve the clinical outcomes of 3023 patients with 
congestive heart failure and preserved left ventricular 
systolic dysfunction (ejection fraction higher than 40%).18 
Cardiovascular death did not differ between groups (170 vs 
170), but fewer patients in the candesartan cilexetil group 
Table 1 Pharmacology and pharmacokinetics of angiotensin receptor blockers
Candesartan Losartan Valsartan Olmesartan Telmisartan Eprosartan Irbesartan
Food  
Interaction
No 10% decrease  
in biov.
Not  
Significant
No 6%–20%  
decrease in biov.
Not  
significant
No
Drug–drug  
interaction  
that may  
require therapy  
modification
Amifostine 
Lithium 
Rituximab
Amifostine 
Lithium 
Fluconazole 
Nicardipine 
Sulfadiazine 
Rituximab
Amifostine 
Lithium 
Rituximab
Amifostine 
Lithium 
Rituximab
Amifostine 
Lithium 
Rituximab 
Digoxin
Amifostine 
Lithium 
Rituximab
Amifostine 
Lithium 
Rituximab
Dose in hepatic 
impairment
Lower dose  
in moderate  
hepatic failure
Lower dose No change  
in dose
No change  
in dose
No change  
in dose
No change  
in dose
No change  
in dose
Dose in renal  
impairment
No change  
in dose
No change  
in dose
No change  
in dose
No change  
in dose
No change  
in dose
No change  
in dose
No change  
in dose
PPAR-G Yes Yes None None Yes None Yes
AT(1) receptor 
binding 
Dissociation 
t½ (min) 
Binding potency 
candesartan = 1
Insur 
 
120 
 
1
Sur 
 
Fast 
EXP = 30 
0.014 
EXP = 0.45
Insur 
 
17 
 
0.17
Insur 
 
75 
 
0.73
Insur 
 
25 
 
0.083
Sur Insur 
 
7 
 
0.15
AT(1) receptor 
selectivity 
versus AT(2)
A C C A C B B
Inverse agonism Yes None Yes Yes None None None
Total daily  
dose (mg)
8–32 50–100 80–320 20–40 40–80 400–800 150–300
Number of  
doses (daily)
1–2 1–2 1–2 1 1 1–2 1
P450 
metabolism
Not  
significant
CYP 2C9  
and 3A4
Unknown No No No CYP 2C9
Protein 
binding
99% High 95% 99% 99.5% 98% 90%
Half life 
(hours)
5–9 6–9 6 13 24 5–9 11–15
Time to peak 
serum (hours)
3–4 3–4 2–4 1–2 0.5–1 1–2 1.5–2
Excretion Urine (26%) Urine (10%) Feces (83%) Feces (50%) 
Urine (50%)
Feces (97%) Feces (90%) 
Urine (7%)
Feces (50%) 
Urine (50%)
Time to BP  
effect (weeks)
2–4 3–6 4 1–2 4 2–3 2
Abbreviations: AT(1), angiotensin type 1 receptor; AT(2), angiotensin type 2 receptor; CYP, cytochrome; EXP, EXP3174, the active metabolite of losartan; PPAR-G, 
peroxisome proliferator activated receptor gamma; A, highest level of affinity; B, second in line after A; C, third in line after A and B; sur, surmountable; insur, insurmountable; 
Biov., bioavailability; BP, blood pressure.
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Table 2 Clinical trials of candesartan cilexetil
Target Study Patient population  
and duration
Treatment added  
to standard therapy
Primary endpoint Benefit
Heart Failure CHARM–Added16 CHF, EF , 40%  
(41 months)
Candesartan +  
ACEI vs ACEI
Reduction in mortality 
and morbidity
Confirmed
CHARM–Alternative17 CHF, EF , 40%,  
intolerant to  
ACEI (33.7 months)
Candesartan vs  
placebo
Reduction in mortality 
and hospital admission
Confirmed
CHARM-Preserved18 CHF, EF . 40%  
(36.6 months)
Candesartan vs  
placebo
Reduction in mortality  
and hospital admission
Moderate 
confirmed
High blood pressure TROPHY19 Prehypertension  
(4 years)
Candesartan vs  
placebo
Prevention HTN Confirmed
Five trials20 HTN ± DM  
(12–14 wks)
Candesartan vs  
placebo
Treatment HTN Confirmed
Candesartan  
comparative trial21
HTN + DM  
(3 months)
Candesartan vs  
telmisartan and  
valsartan
Treatment HTN As good as 
the other two
Candesartan  
comparative trial22
HTN and CHF  
Meta-analysis
Candesartan vs  
losartan
Treatment HTN Better.  
Not cost-
effective
Arterial elasticity CALM II23 HTN + DM  
(12 months)
Candesartan +  
20 mg lisinopril vs  
40 mg lisinopril
Reduction in  
pulse pressure
Confirmed
Large and small  
artery elasticity24
HTN + DM  
(6 months)
32 mg candesartan vs  
16 mg candesartan vs  
placebo
Reduction in  
arterial elasticity
Confirmed
Renal protection SECRET25 Renal graft +  
HTN (3 years)
Candesartan vs  
placebo
Reduction in mortality  
and graft failure
Confirmed
CKD stage 4–526 CKD stage 4–5  
and BP , 140/90  
mmHg (3 years)
Candesartan vs  
placebo
Reduction in mortality  
and hemodialysis 
prevention
Confirmed
CKD stage 1–327 CKD stage 1–3,  
DM, ALB  
(8 months)
Candesartan vs  
placebo
Reduction in ALB Confirmed
Stroke SCOPE28 Aged 70–89 years,  
HTN (3.7 years)
Candesartan vs  
placebo
Reduction in stroke 
and cognitive decline
Confirmed for 
stroke only
ACCESS29 Early stroke,  
HTN (1 year)
Candesartan vs  
placebo
Reduction in mortality  
and morbidity
Confirmed
SCAST30 Within first 30 hours  
after stroke (6 months)
Candesartan vs  
placebo
Better functional  
outcome
Worse  
than placebo
Retinal protection DIRECT-Prevent 131 No RTP + DM type 1,  
no HTN, no ALB (4 years)
Candesartan vs  
placebo
Prevention of RTP Partially  
confirmed
DIRECT-Protect 131 RTP + DM type 1,  
no HTN, no ALB (4 years)
Candesartan vs  
placebo
Reduction in RTP Partially  
confirmed
DIRECT-Protect 232 RTP+DM type 2,  
no HTN, no ALB (4 years)
Candesartan vs  
placebo
Reduction in RTP Partially  
confirmed
New-onset diabetes 
prevention
CASE-J 33,34 HTN + obesity Candesartan vs  
amlodipine
Reduction in  
new-onset DM  
and mortality
Confirmed
Migraine Prophylaxis35 Migraine (12 wks) Candesartan vs  
placebo
Reduction in no. of  
days with headache
Confirmed
Atrial fibrillation J-RHYTHM II36 Paroxysmal AF + HTN  
(1 year)
Candesartan vs  
Amlodipine
Reduction in  
frequency of AF  
episodes
Confirmed 
but not better
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ALB, albuminuria; ARB, angiotensin receptor blocker; BP, blood pressure; CHF, 
chronic heart failure; CKD, chronic kidney disease; DM, diabetes mellitus; EF, ejection fraction; HTN, hypertension; RTP, retinopathy. Clinical studies: ACCESS, Acute 
Candesartan Cilexetil Therapy in Stroke Survivors; CALM II, Candesartan and Lisinopril Microalbuminuria Trial II; CASE-J, Candesartan Antihypertensive Survival Evaluation 
in Japan; CHARM, Candesartan in Heart failure: Assessment of Reduction in Mortality; DIRECT, DIabetic REtinopathy Candesartan Trials; J-RHYTHM II, Japanese Rhythm 
Management Trial II for Atrial Fibrillation; SCAST, Candesartan for Treatment of Acute Stroke; SCOPE, Study on Cognition and Prognosis in the Elderly; SECRET, Study on 
Evaluation of Candesartan Cilexetil after Renal Transplantation; TROPHY, Trial of Preventing Hypertension.
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than in the placebo group were admitted to hospital for 
  congestive heart failure once (230 vs 279, P = 0.017) or 
multiple times. The clinical benefit was also observed 
in patients with nonfatal myocardial infarction, and 
nonfatal stroke.
Hypertension
TROPHY
The trial of preventing hypertension (TROPHY) investigated 
whether candesartan cilexetil along with lifestyle modifica-
tions prevents worsening of prehypertension.19 A total of 
809 participants with repeated measurements of systolic 
BP (SBP) of 130–139 mmHg and diastolic BP (DBP) of 
89 mmHg or lower, or SBP of 139 mmHg or lower and 
DBP of 85–89 mmHg, were randomly assigned to receive 
2 years of candesartan cilexetil (n = 409) or placebo (n = 400), 
followed by 2 years of placebo. All data on 772 participants 
(391 in the candesartan cilexetil group, and 381 in the placebo 
group; mean age, 48.5 years; 59.6% men) were available for 
analysis. During the first 2 years, hypertension developed 
in nearly two-thirds of participants (n = 154) in the placebo 
group and 53 of those in the candesartan cilexetil group 
(relative risk reduction 66.3%, P , 0.001). After 4 years, 
hypertension had developed in 240 participants in the placebo 
group and 208 of those in the candesartan cilexetil group 
(relative risk reduction 15.6%, P , 0.007).
Candesartan cilexetil in the management of BP  
in diabetic and nondiabetic hypertensive patients
A selection of five randomized double-blind clinical trials in 
which patients were treated for hypertension with candesartan 
cilexetil were analyzed.20 All of these were similar in design: 
(1) a 4-week placebo run-in period, (2) a 4- to 6-week 
period (V1) with candesartan cilexetil 8 mg once daily, after 
which the dosage was doubled if BP was not normalized 
(BP . 140/90 or BP . 130/80 mmHg in diabetes), and 
(3) a 4- to 6-week period (V2) with candesartan cilexetil 
8 or 16 mg once daily. Efficacy was measured at V1 and 
V2. Seven hundred and two patients were screened. The 
population consisted of 397 males (56.6%) with a mean 
age of 60 ± 11 years, with 153 diabetic (21.8%) and 549 
nondiabetic (78.2%) patients. At baseline, mean BP values 
were 160/94/65 mmHg for SPB, DBP, and pulse pressure 
(PP) respectively, with differences between diabetic and 
nondiabetic patients. SBP, DBP, and PP values showed a 
significant reduction at V1 (P , 0.001) and V2 (P , 0.001) 
compared with baseline for all hypertensive patients. Mean 
changes at V2 in SBP and PP values were higher in diabetic 
than nondiabetic patients (P , 0.001), and to a lesser degree 
on DBP values (P = 0.034).
Candesartan cilexetil versus telmisartan or valsartan
A total of 308 hypertensive patients with diabetes were 
enrolled in our multicenter, randomized, open-label study.21 
The patients received 40 mg telmisartan, 8 mg candesartan 
cilexetil, or 80 mg valsartan for 3 months, and the data for 
227 patients (telmisartan: n = 74, candesartan cilexetil: n = 79, 
and valsartan: n = 74) were analyzed. The SBP and DBP sig-
nificantly decreased in all the groups at the end of the study; 
the decrease was comparable among the three groups.
Candesartan cilexetil versus losartan
This meta-analysis compared and analyzed as the primary end 
point candesartan cilexetil and losartan in the management 
of hypertension and heart failure.22 The secondary objective 
was to model their comparative incremental cost-effectiveness 
in a UK National Health Service setting. Fourteen studies 
(eight of hypertension and six of heart failure) were included. 
Eight and zero trials compared candesartan cilexetil directly 
with losartan in the treatment of hypertension and heart 
failure, respectively. A between-treatment difference of 
−1.96 mmHg (95% CI: −2.40 to −1.51) for trough DBP and 
−3.00 mmHg (95% CI: −3.79 to −2.22) for trough SBP in 
favor of candesartan cilexetil was observed. Based on this 
differential, a 10-year Markov model estimates the cost 
per quality-adjusted life-year gained to exceed £40,000 
for using candesartan cilexetil in place of generic losartan. 
Candesartan cilexetil reduces BP to a slightly greater extent 
when compared with losartan, however, such a difference 
is unlikely to be cost-effective based on current acquisition 
costs. Robust evidence supporting the superiority of 
candesartan cilexetil over losartan in the treatment of heart 
failure was not found.
Arterial compliance
CALM II
Candesartan And Lisinopril Microalbuminuria trial II 
(CALM) II was a 12-month prospective, randomized, 
parallel-group, double-masked study that included 75 type 1 
and type 2 diabetic subjects with hypertension.23 Participants 
were randomized to treatment with either high-dose lisinopril 
(40 mg once daily [od]) or for dual blockade treatment with 
candesartan cilexetil (16 mg od) and lisinopril (20 mg od). The 
effect of 12 months of dual blockade with candesartan cilex-
etil and lisinopril versus high-dose lisinopril monotherapy on 
ambulatory PP of 51 participants with type 2 diabetes who 
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completed the full 12-month study period with successful 
ambulatory BP measurements at both baseline and follow-up 
visits was examined. Compared with lisinopril monotherapy, 
dual blockade treatment caused a highly significant reduction 
in 24-hour PP levels (−5 ± 5 mmHg, P = 0.003), albeit the 
difference in the BP lowering effect between the treatment 
groups did not differ significantly for 24-hour SBP (P = 0.21) 
or DBP (P = 0.49). Dual blockade treatment significantly 
lowered 24-hour SBP (−5 ± 11 mmHg, P = 0.03), but not 
24-hour DBP (−2 ± 7 mmHg, P = 0.29), whereas in the 
lisinopril group, the opposite effect was observed (24-hour 
SBP −1 ± 9 mmHg, P = 0.45; 24-hour DBP −3 ± 7 mmHg, 
P = 0.03).
Arterial elasticity
The effect of candesartan cilexetil on arterial elasticity, 
inflammatory, and metabolic parameters in hypertensive 
patients with multiple cardiovascular risk factors was 
assessed.24 69 hypertensive patients were randomized into 
three groups: group 1 included patients treated with high 
doses of   candesartan cilexetil (32 mg), group 2 included 
patients treated with conventional doses of candesartan 
cilexetil (16 mg), and group 3 included patients who received 
antihypertensive treatment other than ARBs or angiotensin-
converting enzyme inhibitors. Arterial elasticity was 
evaluated using pulse wave contour analysis method (HDI CR 
2000, Eagan, Minnesota). In patients treated with high doses 
of candesartan cilexetil: large artery elasticity index (LAEI) 
increased from 8.6 ± 2.8 to 16.6 ± 5.1 mL/mmHg × 100 
after 6 months of treatment (P , 0.0001). Small artery 
elasticity index (SAEI) increased from 2.7 ± 1.3 to 5.9 ± 
2.8 mL/mmHg × 100 (P , 0.0001). Systemic vascular 
resistance decreased from 1881.5 ± 527.5 to 1520.9 ± 271.8 
(P , 0.0006). In patients treated with conventional doses of 
candesartan cilexetil: LAEI index increased from 11.0 ± 3.5 
to 14.4 ± 3.2 mL/mmHg × 100 (P , 0.0001). SAEI increased 
  during the study from 3.7 ± 1.4 to 5.4 ± 2.1 mL/mmHg × 100 
(P , 0.0001).   Systemic vascular resistance decreased from 
1699.8 ± 327.6 to 1400.7 ± 241 (P , 0.0001). In the control 
group: neither LAEI nor SAEI improved during the treatment 
period. Although similar reduction in BP was observed in all 
three groups, both LAEI and SAEI improved only in patients 
treated with ARBs.
Renal protection
SECRET
The Study on Evaluation of Candesartan cilexetil after Renal 
Transplantation (SECRET): an international multicenter, 
double-blind, randomized investigation of candesartan 
cilexetil versus placebo in renal allograft recipients was 
originally designed to study 700 patients for 3 years.25 The 
candesartan cilexetil dose was escalated from 4 to 16 mg daily, 
followed by addition of comedication, if needed, with the aim 
of achieving a DBP , 85 mmHg. The primary efficacy vari-
able was a composite of all-cause mortality, cardiovascular 
morbidity, and graft failure. SECRET was stopped prema-
turely as the primary event rate was much lower than expected. 
At that point, 502 patients were enrolled; 255 received can-
desartan cilexetil and 247 placebo. Thirteen primary events 
had occurred in each group. Control of both SBP and DBP 
was better in the candesartan cilexetil group. Urinary protein 
excretion and protein/creatinine ratio decreased on candesar-
tan cilexetil but increased on placebo. Serum creatinine and 
potassium were increased in candesartan cilexetil patients, 
but these changes were generally small.
Patients with stage 4–5 chronic kidney disease
Candesartan cilexetil was administered to 13 patients (cande-
sartan group, n = 7; control group, n = 6) with a serum creati-
nine level of 2.52–5.95 mg/dL whose BP had been maintained 
below 140/90 mmHg by the use of drugs other than ARBs.26 
Routine measurements were conducted for 48 weeks, and 
renal survival analysis was observed for up to 3 years with the 
endpoints being doubling of the serum creatinine level, entry 
to hemodialysis, or death. The results were compared with 
those of the control group that was not treated with ARBs. 
No significant changes were observed in BP in either group. 
Proteinuria significantly decreased from 0.95 ± 0.51 to 0.39 ± 
0.12 g/day (paired t test, P = 0.033) in the ARB group, but did 
not change in the control group. Creatinine clearance in the 
control group decreased significantly from 16.2 ± 5.7 to 10.4 ± 
4.8 mL/min per 1.73 m2 (paired t-test, P = 0.011), but did not 
change in the other group. Thus, the slopes of the reciprocal 
serum creatinine values became less steep in the candesartan 
cilexetil group as compared with the control (−0.002 ± 0.015 vs 
−0.025 ± 0.015 dL/mg per month; unpaired t-test, P = 0.019). 
Kaplan–Meier analysis revealed that ARBs exhibited more 
favorable renal outcomes at 3 years (log-rank, P = 0.025). No 
serious adverse events were noted in the study. These results 
show that candesartan cilexetil reduces proteinuria and protects 
renal function even in advanced renal failure.
Patients with mild-to moderate renal failure,  
type 2 diabetes, and proteinuria
A total of 23 hypertensive patients with type 2   diabetes 
and nephropathy were enrolled in this double-blind, 
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  randomized cross-over trial with four treatment periods, 
each lasting 2 months.27 Each patient received placebo and 
candesartan cilexetil: 8, 16, and 32 mg daily in random 
order. Antihypertensive medication was discontinued before 
enrollment, except for long-acting furosemide, which all 
patients received throughout the study in median (range) doses 
of 40 (30–160) mg daily. Endpoints were albuminuria, 24-hour 
BP, and glomerular filtration rate (GFR). Values obtained dur-
ing placebo treatment: albuminuria (geometric mean [95% 
CI]) 700 (486–1007) mg/24-hour; 24-hour BP (mean ± SE) 
147 ± 4/78 ± 2 mmHg, and GFR 84 ± 6 mL/min/1.73 m2. 
All three doses of candesartan cilexetil significantly reduced 
albuminuria and 24-hour BP compared with placebo. Mean 
reductions in albuminuria were 33% (95% CI: 21–43), 59% 
(95% CI: 52–65), and 52% (95% CI: 44–59) with increasing 
doses of candesartan cilexetil. Albuminuria was reduced 
  significantly more by the two highest doses than by the low-
est dose (P , 0.01); 24-hour SBP was reduced by 9 (95% 
CI: 2–16), 9 (95% CI: 2–16), and 13 (95% CI: 6–20) mmHg, 
and 24-hour DBP was reduced by 5 (95% CI: 2–8), 4 (95% 
CI: 1–7), and 6 (95% CI: 3–9) mmHg with increasing doses 
of candesartan cilexetil. There were no significant differences 
in the reductions in BP between the three doses. GFR was 
decreased by approximately 6 mL/min/1.73 m2 by all three 
doses of candesartan cilexetil (P , 0.05 vs placebo).
Stroke
SCOPE
The Study on COgnition and Prognosis in the Elderly 
(SCOPE) assessed whether candesartan cilexetil-based 
antihypertensive treatment in elderly patients with mildly 
to moderately elevated BP confers a reduction in fatal and 
nonfatal stroke, cardiovascular events, cognitive decline, and 
dementia.28 The study included 4964 patients aged 70–89 
years with SBP 160–179 mmHg, and/or DBP 90–99 mmHg. 
A total of 527 centers in 15 countries participated in the study. 
Patients were assigned randomly to receive candesartan 
cilexetil or placebo, with open-label active antihypertensive 
therapy added as needed. As a consequence, active anti-
hypertensive therapy was extensively used in the control 
group (84% of patients). Mean follow-up was 3.7 years. BP 
fell by 21.7/10.8 mmHg in the candesartan cilexetil group 
and by 18.5/9.2 mmHg in the control group. A first major 
cardiovascular event occurred in 242 candesartan cilexetil 
patients and in 268 control patients; risk reduction with 
candesartan cilexetil was 10.9% (95% CI: −6.0 to 25.1, 
P = 0.19). Candesartan cilexetil-based treatment reduced 
nonfatal stroke by 27.8% (95% CI: 1.3 to 47.2, P = 0.04), 
and all stroke by 23.6% (95% CI: −0.7 to 42.1, P = 0.056). 
There were no significant differences in myocardial infarction 
and cardiovascular mortality. Mean MMSE score fell from 
28.5 to 28.0 in the candesartan cilexetil group and from 28.5 
to 27.9 in the control group (P = 0.20). The proportions of 
patients who had a significant cognitive decline or developed 
dementia were not different in the two treatment groups.
ACCESS
The Acute Candesartan Cilexetil therapy in Stroke Survivors 
(ACCESS) study was designed to assess the safety of modest 
BP reduction by candesartan cilexetil in the early treatment 
of stroke.29 500 patients were recruited in a prospective, 
double-blind, placebo-controlled, randomized study. This 
safety trial was stopped prematurely when 342 patients 
(339 valid) had been randomized because of an imbalance 
in endpoints. Demographic data, cardiovascular risk factors, 
and BP on admission, on study onset, and within the whole 
study period were not significantly different between the two 
groups. However, the cumulative 12-month mortality and the 
number of vascular events differed significantly in favor of 
the candesartan cilexetil group (odds ratio [OR]: 0.475, 95% 
CI: 0.252–0.895).
SCAST
Candesartan for treatment of acute stroke (SCAST) was 
designed to study whether careful BP lowering treatment 
with candesartan cilexetil is beneficial in patients with 
acute stroke and raised BP.30 2029 patients were randomly 
allocated to treatment groups (1017 candesartan cilexetil, 
1012 placebo), within 30 hours of stroke onset, for 7 days, 
with doses increasing from 4 mg on day 1 to 16 mg on days 
3–7. During the 7-day treatment period, BP was significantly 
lower in patients allocated candesartan cilexetil than in 
those on placebo (mean 147/82 mmHg in the candesartan 
cilexetil group on day 7 vs 152/84 mmHg in the placebo 
group, P , 0.0001). During 6 months’ follow-up, the risk 
of the composite vascular endpoint did not differ between 
treatment groups (candesartan cilexetil 120 events vs   placebo 
111 events, adjusted hazard ratio [HR]: 1.09, 95% CI: 0.84–
1.41, P = 0⋅52). Analysis of functional outcome suggested 
a higher risk of poor outcome in the candesartan cilexetil 
group (adjusted common OR: 1.17, 95% CI: 1.00–1.38, 
P = 0⋅048 [not significant at P # 0.025 level]). The observed 
effects were similar for all prespecified secondary endpoints 
(including death from any cause, vascular death, ischemic 
stroke, hemorrhagic stroke, myocardial infarction, stroke 
progression, symptomatic hypotension, and renal failure) 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
755
Candesartan compared to other angiotensin receptor blockersVascular Health and Risk Management 2011:7
and outcomes, and there was no evidence of a differential 
effect in any of the prespecified subgroups. During follow-up, 
nine (1%) patients on candesartan cilexetil and five (,1%) 
on placebo had symptomatic hypotension, and renal failure 
was reported for 18 (2%) patients taking candesartan cilexetil 
and 13 (1%) allocated placebo.
Retinopathy
DIRECT-Prevent 1 and DIRECT-Protect 1
DIabetic REtinopathy Candesartan Trials (DIRECT) assessed 
the effect of candesartan cilexetil on prevention (DIRECT-
Prevent 1) and progression (DIRECT-Protect 1) of retinopa-
thy in type 1 diabetes.31 Participants aged 18–55 years, with 
normotensive, normoalbuminuric type 1 diabetes without 
retinopathy were recruited to the DIRECT-Prevent 1 trial 
(n = 710 candesartan cilexetil/710 placebo) and those with 
existing retinopathy were recruited to DIRECT-Protect 1 
(n = 1905 candesartan cilexetil/954 placebo), and prospec-
tively randomized to candesartan 16 mg once a day or 
matching placebo. After 1 month, the dose was doubled to 
32 mg. The primary endpoints were incidence and progres-
sion of retinopathy and were defined as at least a two-step 
and at least a three-step increase on the Early Treatment 
Diabetic Retinopathy Study scale, respectively. Incidence 
of retinopathy was seen in 178 (25%) participants in the 
candesartan cilexetil group versus 217 (31%) in the placebo 
group. Progression of retinopathy occurred in 127 (13%) 
participants in the candesartan cilexetil group versus 124 
(13%) in the placebo group. HR for candesartan cilexetil 
versus placebo was 0.82 (95% CI: 0.67–1.00, P = 0.0508) 
for incidence of retinopathy and 1.02 (95% CI: 0.80–1.31, 
P = 0.85) for progression of retinopathy. The post-hoc out-
come of at least a three-step increase for incidence yielded 
an HR of 0.65 (95% CI: 0.48–0.87, P = 0.0034), which was 
attenuated but still significant after adjustment for baseline 
characteristics (0.71, 95% CI: 0.53–0.95, P = 0.046). Final 
Early Treatment Diabetic Retinopathy Study scale level 
was more likely to have improved with candesartan cilexetil 
treatment in both DIRECT-Prevent 1 (OR: 1.16, 95% CI: 
1.05–1.30, P = 0.0048) and DIRECT-Protect 1 (1.12, 95% 
CI: 1.01–1.25, P = 0.0264).
DIRECT-Protect 2
DIRECT-Protect 2 evaluated the effect of candesartan 
cilexetil on progression and regression of retinopathy in 
type 2 diabetes.32 1905 normoalbuminuric, normotensive, 
or treated hypertensive participants (aged 37–75 years) with 
type 2 diabetes with mild to moderately severe retinopathy 
were randomized to candesartan cilexetil 16 mg once a day 
(n = 951) or placebo (n = 954). After 1 month, the dose was 
doubled to 32 mg once per day. Progression of retinopathy 
was the primary endpoint, and regression was a secondary 
endpoint. 161 (17%) patients in the candesartan cilexetil 
group and 182 (19%) in the placebo group had progression 
of retinopathy by three steps or more on the Early Treatment 
Diabetic Retinopathy Study scale. The risk of progression of 
retinopathy was nonsignificantly reduced by 13% in patients 
on candesartan cilexetil compared with those on placebo (HR: 
0.87, 95% CI: 0.70–1.08, P = 0.20). Regression on active 
treatment was increased by 34% (HR: 1.34, 95% CI: 1.08–
1.68, P = 0.009). HRs were not attenuated by adjustment for 
baseline risk factors or changes in BP during the trial. An 
overall change towards less severe retinopathy by the end 
of the trial was observed in the candesartan cilexetil group 
(OR: 1.17, 95% CI: 1.05–1.30, P = 0.003). Adverse events 
did not differ between the treatment groups.
New-onset diabetes prevention
CASE-J trial
The Candesartan Antihypertensive Survival Evaluation in 
Japan (CASE-J) trial was a prospective, randomized, open-
label study designed to compare the long-term effects of 
candesartan cilexetil and amlodipine on the incidence of 
cardiovascular events, represented as a   composite of sudden 
death and cerebrovascular, cardiac, renal, and vascular 
events in high-risk Japanese hypertensive patients.33,34 
4728 patients (mean age 63.8 years; mean body mass 
index [BMI] 24.6 kg/m2) were followed for an average 
of 3.2 years. The role of pre-existing diabetes or obesity 
on these outcomes were subanalyzed using a multivari-
ate Cox regression model. BP was well controlled with 
both treatment-based regimens (136.1/77.3 mmHg for 
candesartan cilexetil-based regimens and 134.4/76.7 mmHg 
for amlodipine-based   regimens after 3 years). Primary 
cardiovascular events occurred in 134 patients with both 
the candesartan cilexetil- and amlodipine-based regimens. 
The two treatment-based regimens produced no significant 
differences in cardiovascular morbidity or mortality in all 
high-risk Japanese hypertensive patients (HR: 1.01, 95% 
CI: 0.79–1.28, P = 0.969), but all-cause mortality was 
significantly higher with amlodipine than with candesartan 
cilexetil among patients with BMI $ 27.5 kg/m2 (adjusted 
HR: 0.32, range: 0.13–0.75, P = 0.009). New-onset diabetes 
occurred in fewer patients taking candesartan cilexetil 
(8.7/1000 person-years) than in those taking amlodipine 
(13.6/1000 person-years), which resulted in a 36% relative 
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risk reduction (HR: 0.64, 95% CI: 0.43–0.97, P = 0.033). 
Moreover, the increase in new-onset diabetes was   dependent 
on BMI among patients receiving amlodipine, whereas 
no such dependency was noticed for candesartan cilexetil 
(interaction P = 0.016). Candesartan cilexetil treatment may 
reduce all-cause death and decrease the incidence of new-
onset diabetes in obese patients.
Migraine
Candesartan cilexetil was evaluated in a prospective, ran-
domized, double-blind, crossover study in 60 patients with 
migraine.35 Candesartan cilexetil 16 mg per day was found to 
reduce the mean number of days with headache and migraine 
compared with placebo (13.6 vs 18.5 days, respectively, 
with headache [P = 0.001]; 9.0 vs 12.6 days, respectively, 
with migraine [P , 0.001]). Candesartan cilexetil also 
appeared to significantly decrease headache severity, level of 
  disability, and days of sick leave due to headache. The rate 
of response to candesartan cilexetil, based on a 50 percent 
or more reduction in the number of days with migraine, 
was 40.4%, compared with 3.5% for placebo (P , 0.001). 
Adverse effects with candesartan cilexetil were similar to 
those with placebo.
Atrial fibrillation
J-RHYTHM II
The Japanese Rhythm management trial II for atrial fibril-
lation (J-RHYTHM II study) is an open-label randomized 
comparison between an ARB (candesartan cilexetil) and 
a calcium channel blocker (CCB) (amlodipine) in the 
treatment of paroxysmal atrial fibrillation associated with 
  hypertension.36 Using daily transtelephonic monitoring, we 
examined asymptomatic and symptomatic   paroxysmal atrial 
fibrillation episodes during a maximum 1 year   treatment. 
The primary endpoint was the difference in atrial fibril-
lation frequency between the pretreatment period and the 
final month of the follow-up. The secondary endpoints 
included cardiovascular events, development of persistent 
atrial fibrillation, left atrial dimension, and quality-of-life 
(QOL). The study enrolled 318 patients (aged 66 years, male/
female 219/99, 158 in the ARB group and 160 in the CCB 
group) treated at 48 sites throughout Japan. At baseline, the 
frequency of atrial fibrillation episodes (days/month) was 
3.8 ± 5.0 in the ARB group versus 4.8 ± 6.3 in the CCB group 
(not significant). During the follow-up, BP was significantly 
lower in the CCB group than in the ARB group (P , 0.001). 
The atrial fibrillation frequency decreased similarly in both 
groups, and there was no significant difference in the primary 
endpoint between the two groups. There were no significant 
differences between the two groups in the development of 
persistent atrial fibrillation, changes in left atrial dimension, 
occurrence of cardiovascular events, or changes in QOL.
Comparative safety and tolerability
Candesartan cilexetil as other ARBS is generally well 
tolerated and the incidence of discontinuation is comparable 
with that of placebo. Candesartan cilexetil does not cause 
cough and the incidence of angioedema is low. In patients 
whose BP is highly dependent on the renin-angiotensin 
system candesartan cilexetil can cause hypotension, oliguria, 
renal failure, and hyperkalemia. Candesartan cilexetil 
should be used cautiously in patients with renal failure 
who are taking potassium supplements or spironolactone 
to avoid hyperkalemia. The dose of candesartan cilexetil 
must be adjusted when it is administered along with other 
antihypertensive drugs to prevent hypotension.37–42
Many of the hypertensive patients have not responded 
adequately to candesartan cilexetil alone. Administration of 
α-blockers, β-blockers, diuretics, and calcium antagonists 
along with candesartan cilexetil is safe and effective.16–18,33,34
ARBs are known to cause fetal malformations and neonatal 
problems if administered during pregnancy and this can 
prove an impediment to their use in women of child-bearing 
potential. The teratogenic potential of RAS-inhibiting/
blocking agents administered during the second and third 
trimesters of pregnancy is well established. Abnormalities 
reported include fetal craniofacial abnormalities and limb 
contractures, probably consequent to oligohydramnious 
and failed renal development. An interesting report checked 
teratogenity of candesartan cilexetil in the first trimester. 
615 (43.3%), 813 (42.7%), and 957 (50.2%) women were 
randomized to either candesartan cilexetil 32 mg once 
daily, or placebo in DIRECT-Prevent 1, DIRECT-Protect 
1 and DIRECT-Protect 2, respectively. Of the women who 
were randomized and took at least one dose of study drug, 
178 patients (73 from Prevent 1 and 105 from Protect 
(1) became pregnant (86 from the candesartan cilexetil and 
92 from the placebo groups). Delivery outcomes were similar 
for the candesartan cilexetil and placebo groups: full term 
delivery (51 candesartan cilexetil, 50 placebo), premature 
birth (21 candesartan cilexetil, 27 placebo), spontaneous 
miscarriage (12 candesartan cilexetil, 15 placebo),   elective 
termination (15 candesartan cilexetil, 14 placebo), and 
other (1 candesartan cilexetil, 2 placebo). Most infants 
were healthy, whether full term or premature. There were 
two stillbirths in the candesartan cilexetil group and one in 
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the placebo group, and two ‘sick babies’ in the candesartan 
cilexetil group and eight in the placebo group. The only con-
genital malformation reported was a ventricular septal defect 
in the placebo group. The DIRECT   experience indicates that 
exposure to a relatively high dosage of candesartan cilexetil, 
32 mg/day, for up to 8 weeks into the first trimester of preg-
nancy may not result in a higher rate of malformations than 
placebo in normotensive normoalbuminuric women with 
type 1 diabetes.31,32,41
Candesartan cilexetil therapy was generally well 
  tolerated in clinical studies in children and adolescents 
with hypertension. The pharmacokinetic profile was 
  independent of age, sex, and weight, and was similar to that 
in adults.42,43
Candesartan cilexetil and four other ARBS were assessed 
for the incidence of cancer in 15 large parallel long-
term multicenter double blind clinical trials involving 
138,769 participants. The four candesartan cilexetil trials 
were CHARM, DIRECT 1, SCOPE, and TROPHY. The 
CHARM Overall program consisted of three separate trials in 
heart failure patients, including CHARM-Added, CHARM-
Alternative and CHARM-Preserved. In CHARM Overall, 
6.8% of patients had preexisting cancers at baseline. There 
was no significant difference in cancer incidence between 
active and control treatment in any of the individual trials, 
except for the DIRECT trials in which the cancer incidence 
was 1.80% in patients randomized to candesartan cilexetil 
and 1.07% in patients on control treatment (OR: 1.69, 95% 
CI: 1.06–2.71) From this meta-analysis on 138,679 patients in 
the 15 major trials of the five ARBs, there was no significant 
excess in cancer incidence with ARB treatment compared 
to controls with any individual ARB and overall.   Moreover, 
including CHARM together with the entire previous 
candesartan cilexetil placebo-controlled trial experience, 
no consistent differences in fatal and nonfatal neoplasms at 
different sites have been noted between candesartan cilexetil 
and placebo. There was no excess of common cancers, 
ie, lung, prostrate, or breast.16–19,28,44
Conclusion
Candesartan cilexetil is an effective antihypertensive 
agent with a tolerability profile similar to that of placebo. 
Comparative data indicate that candesartan cilexetil has anti-
hypertensive efficacy as good as or better than that of other 
major ARBS and has a long duration of action. Regression of 
left ventricular hypertrophy has been seen with candesartan 
cilexetil treatment in patients with hypertension. Therefore, 
candesartan cilexetil is a useful therapeutic option in the 
management of patients with hypertension and heart failure. 
Candesartan cilexetil has also been proven to be effective 
in the prevention and progression of renal disease, retinal 
disease, and stroke.
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